We contemplate the use of IP2 to enlarge the pool of targetable tumor-associated (TAAs) and tumor-specific (TSAs) antigens from different regions of the genome in the context of epitope-based immunotherapies. The gene discussed is IKBKG; the disease is neoplasm.